Thus, while modulation of TRM survival through IL-15, TGF-β, or IL-4 pathways represents a conceptual curative strategy for rapid-onset ACD, its clinical feasibility and safety remain uncertain and require cautious investigation in human trials. Here, IL15 is linked to granular corneal dystrophy type II.